Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BIL | DNA | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $16.14 |
52-Week Low | $91.27 | $5.48 |
Market Cap | — | $590.53M |
Enterprise Value | — | $627.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
